Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Jurado

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Molecular Neurodegeneration Advances|June 15, 2026
STIP1/HOP promotes the formation of cytotoxic α-synuclein oligomersBenjamin S Rutledge, Carter J Wilson, Rachel M Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
European Journal of Neurology|November 25, 2017
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive studyC Domínguez, P Pozo-Rosich, M Torres-Ferrús, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Molecular Neurodegeneration Advances|June 15, 2026
STIP1/HOP promotes the formation of cytotoxic α-synuclein oligomersBenjamin S Rutledge, Carter J Wilson, Rachel M Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
European Journal of Neurology|November 25, 2017
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive studyC Domínguez, P Pozo-Rosich, M Torres-Ferrús, et al.
Pageof 6